Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21202616 | 0.85 | L3MBTL1 (0.79) | MAPK1POLBKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL13033213 | 0.85 | L3MBTL1 (0.97) | MAPK1POLBKDM4EL3MBTL1MAPT | |
| SCHEMBL13033211 | 0.84 | MAPK1 (0.77) | MAPK1POLBKDM4EL3MBTL1MAPT | |
| SCHEMBL13033173 | 0.83 | MAPK1 (0.78) | MAPK1POLBKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL15425915 | 0.82 | L3MBTL1 (0.75) | MAPK1POLBKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL8340827 | 0.81 | ABCB1 (0.97) | MAPK1POLBMAPTSMN1; SMN2ABCB1 | |
| SCHEMBL13033210 | 0.76 | L3MBTL1 (0.65) | MAPK1POLBKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL13033140 | 0.76 | L3MBTL1 (0.65) | MAPK1POLBKDM4EL3MBTL1MAPT | |
| SCHEMBL13033206 | 0.75 | MAPK1 (0.65) | MAPK1POLBKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL13033199 | 0.75 | L3MBTL1 (0.64) | MAPK1POLBKDM4EL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2014011917-A2 | A METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| WO-2014012054-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATENT | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20100279996-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BARBIER LINDSAY BURNS | 2010-11-04 | — | — | US | disclosed |
| US-20100279996-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BARBIER LINDSAY BURNS | 2010-11-04 | — | — | US | disclosed |
| US-20100279997-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS | 2010-11-04 | — | — | US | disclosed |
| WO-2010051374-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363239-B2 | Method for inhibiting growth of cancer cells | FLNA, FLNB, FSCN1 | MAPK1 10/4885POLB 2667/4885KDM4E 3556/4885 |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | MAPK1 45/4885POLB 2356/4885KDM4E 2906/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | MAPK1 45/4885POLB 2356/4885KDM4E 2906/4885 |
| US-20100279996-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | FLNA, OPRL1, FLNB | MAPK1 3237/4885POLB 3910/4885KDM4E 4431/4885 |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | MAPK1 45/4885POLB 2356/4885KDM4E 2906/4885 |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | MAPK1 45/4885POLB 2356/4885KDM4E 2906/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | MAPK1 45/4885POLB 2356/4885KDM4E 2906/4885 |
| US-20100279997-A1 | ANALGESIC THAT BINDS FILAMIN A | FLNA, FLNB, OPRL1 | MAPK1 2746/4885POLB 3928/4885KDM4E 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.